topiramate versus valproate sodium as adjunctive therapies to a combination of lithium and risperidone for adolescents with bipolar i disorder: effects on weight and serum lipid profiles.

نویسندگان

javad mahmoudi-gharaei department of psychiatry, roozbeh hospital, tehran university of medical sciences, tehran, iran ; psychiatry and psychology research center, roozbeh hospital, tehran university of medical sciences, tehran, iran.

zahra shahrivar

toktam faghihi

mohammad reza mohammadi

چکیده

to compare the effects of topiramate versus valproate sodium as an add-on therapy to a combination of lithium and risperidone (li+ris) on body weight and serum lipid profile in children and adolescents with bipolar disorder.in a single-blind randomized clinical trial, thirty children and adolescents with bipolar disorder type i in the manic or mixed phase, treated with the combination of li+ris at therapeutic doses for at least 4 weeks who had the indication of add-on therapy due to a recurrent episode; a partial response or non response in the current episode or relapse were included. participants were randomly assigned to receive either topiramate or sodium valproate as the third drug add-on therapy for a total of 6 weeks. weight, height and serum lipid profiles were determined at baseline and at the end of week 6.differences in the mean levels of lipid profiles at baseline and after week 6 evaluation were not significant in both treatment groups. bmi z-score increased in both treatment groups, being significant only in the li+ris/valproate group, increasing from (mean±sd) 0.38±0.55 to 0.72±1.23 (p<0.05). between group changes in bmi z-score was not significant.among the bmi percentile categories, participants in the normal weight subgroup showed a significant increase in bmi z-score during the 6 week trial, compared to overweight/obese subgroup, in both li+ris/valproate and li+ris/topiramate treatment groups. elevated mean serum level of triglyceride and a high proportion of participants with elevated total cholesterol (≥ 170 mg/dl), triglyceride (≥ 110 mg/dl), and bmi percentile 85-<95 at baseline (before randomization) and at the end of 6 week study were noted.when topiramate and valproate sodium are used for six weeks as adjunctive treatment to a combination of li+ris, they act alike on lipid milieu of children and adolescents with bipolar disorder. both li+ris/valproate and li+ris/topiramate therapies can lead to an increase in bmi z-score. this increase is statistically significant with li+ris/valproate therapy. this suggests that topiramate could attenuate the ongoing weight gain from lithium and risperidone. in this study, the majority of participants who gained weight were those with bmi less than 85th percentile. this suggests that normal weight patients may have greater weight gain potential than overweight/obese patients.high proportion of metabolic abnormalities among the patients at baseline, which remained elevated throughout the trial, warrants cardiometabolic monitoring in this population.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Topiramate versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles

OBJECTIVE To compare the effects of topiramate versus valproate sodium as an add-on therapy to a combination of lithium and risperidone (Li+Ris) on body weight and serum lipid profile in children and adolescents with bipolar disorder. METHODS In a single-blind randomized clinical trial, thirty children and adolescents with bipolar disorder type I in the manic or mixed phase, treated with the ...

متن کامل

Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial

Background: In the treatment of bipolar disorder in youths, often more than one medication should be prescribed. In the current study, we compared the efficacy and tolerability of the combination of lithium and quetiapine with lithium and risperidone in the treatment of manic or mixed episodes in children and adolescents. Methods: Thirty patients (aged 10-18 years) who were hospitalized for ...

متن کامل

valproate-risperidone versus valproate-lithium combination in acute mania

background: we evaluated the efficacy of valproate plus risperidone versus valproate plus lithium combination in the treatment of acute mania. methods: in 2-week, randomized, double-blind, parallel group study, 46 acute manic patients according to dsm-iv criteria were randomly assigned to receive combination of valproate 20 mg/ kg/day plus risperidone 2-4 mg/day (n=23) or lithium600-1200 mg/day...

متن کامل

Double-blind, Randomized, Clinical Trial of Topiramate versus Sodium Valproate for the Treatment of Bipolar Disorder in Adolescents

Objective: To study the efficacy and safety of Topiramate versus Sodium Valproate for the Treatment of Bipolar Disorder in Adolescents Methodology: One hundred twenty adolescents (aged 12-18) with an admission diagnosis of bipolar I disorder, manic or mixed episode were enrolled from the Adolescent Ward at Ebn-e-Sina Psychiatric Center of Mashhad University. They were assigned to receive 8 week...

متن کامل

توپیرامات و والپروات سدیم همراه با لیتیوم به‌عنوان درمان کمکی در اختلال دوقطبی نوجوانان: کارآزمایی بالینی تصادفی‌شده

AbstractObjectives: In this study the effect of topiramate as adjunctive therapy to lithium on mood disorder in adolescents is compared to that of sodium valproate.Method: In a randomized clinical trial, 30 adolescents with bipolar mood disorder in the manic or mixed phase were treated with either topiramate or sodium valproate. All participants had either not responded adequately to a 4 to 6 w...

متن کامل

Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder

Lurasidone (DS-RAn) has demonstrated efficacy in the acute treatment of bipolar depression, both as monotherapy, and as combination therapy with lithium or valproate. To evaluate the recurrence prevention efficacy of lurasidone for the maintenance treatment of bipolar I disorder, patients received up to 20 weeks of open-label lurasidone (20-80mg/d) combined with lithium or valproate during an i...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of psychiatry

جلد ۷، شماره ۱، صفحات ۱-۱۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023